Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I
- Supplementary File 1:
PDF-Document (PDF, 295 KiB)
Shkodra, B.; Press, A.T.; Vollrath, A.; Nischang, I.; Schubert, S.; Hoeppener, S.; Haas, D.; Enzensperger, C.; Lehmann, M.; Babic, P.; Benecke, K.J.; Traeger, A.; Bauer, M.; Schubert, U.S. Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I. Pharmaceutics 2020, 12, 1110. https://doi.org/10.3390/pharmaceutics12111110
Shkodra B, Press AT, Vollrath A, Nischang I, Schubert S, Hoeppener S, Haas D, Enzensperger C, Lehmann M, Babic P, Benecke KJ, Traeger A, Bauer M, Schubert US. Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I. Pharmaceutics. 2020; 12(11):1110. https://doi.org/10.3390/pharmaceutics12111110
Chicago/Turabian StyleShkodra, Blerina; Press, Adrian T.; Vollrath, Antje; Nischang, Ivo; Schubert, Stephanie; Hoeppener, Stephanie; Haas, Dorothee; Enzensperger, Christoph; Lehmann, Marc; Babic, Petra; Benecke, Kay J.; Traeger, Anja; Bauer, Michael; Schubert, Ulrich S. 2020. "Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I" Pharmaceutics 12, no. 11: 1110. https://doi.org/10.3390/pharmaceutics12111110